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Abstract
AIM
To establish a rat model of anal sphincter injury and 
test different systems to provide stem cells to injured 
area.
METHODS
Adipose-derived stem cells (ASCs) were isolated from 
BDIX rats and were transfected with green fluorescent 
protein (GFP) for cell tracking. Biosutures (sutures 
covered with ASCs) were prepared with 1.5 x 106 GFP-
ASCs, and solutions of 106 GFP-ASCs in normal saline 
were prepared for injection. Anorectal normal anatomy 
was studied on Wistar and BDIX female rats. Then, 
we designed an anal sphincter injury model consisting 
of a 1-cm extra-mucosal miotomy beginning at the 
anal verge in the anterior middle line. The sphincter 
lesion was confirmed with conventional histology 
(hematoxylin and eosin) and immunofluorescence with 
4', 6-diamidino-2-phenylindole (commonly known as 
DAPI), GFP and α-actin. Functional effect was assessed 
with basal anal manometry, prior to and after injury. 
After sphincter damage, 36 BDIX rats were randomized 
to three groups for: (1) Cell injection without repair; 
(2) biosuture repair; and (3) conventional suture repair 
and cell injection. Functional and safety studies were 
conducted on all the animals. Rats were sacrificed after 
1, 4 or 7 d. Then, histological and immunofluorescence 
studies were performed on the surgical area.
RESULTS
With the described protocol, biosutures had been 
covered with at least 820000-860000 ASCs, with 
100% viability. Our studies demonstrated that some 
ASCs remained adhered after suture passage through 
the muscle. Morphological assessment showed that 
the rat anal anatomy is comparable with human 
anatomy; two sphincters are present, but the external 
sphincter is poorly developed. Anal sphincter pressure 
data showed spontaneous, consistent, rhythmic 
anal contractions, taking the form of “plateaus” with 
multiple twitches (peaks) in each pressure wave. 
These basal contractions were very heterogeneous; 
their frequency was 0.91-4.17 per min (mean 1.6980, 
SD 0.57698), their mean duration was 26.67 s and 
mean number of peaks was 12.53. Our morphological 
assessment revealed that with the aforementioned 
surgical procedure, both sphincters were completely 
sectioned. In manometry, the described activity 
disappeared and was replaced by a gentle oscillation of 
basal line, without a recognizable pattern. Surprisingly, 
these findings appeared irrespective of injury repair or 
not. ASCs survived in this potentially septic area for 7 
d, at least. We were able to identify them in 84% of 
animals, mainly in the muscular section area or in the 
tissue between the muscular endings. ASCs formed a 
kind of “conglomerate” in rats treated with injections, 
while in the biosuture group, they wrapped the suture. 
ASCs were also able to migrate to the damaged zone. 
No relevant adverse events or mortality could be 
related to the stem cells in our study. We also did not 
find unexpected tissue growths. 
CONCLUSION
The proposed procedure produces a consistent sphinc-
ter lesion. Biosutures and injections are suitable for cell 
delivery. ASCs survive and are completely safe in this 
clinical setting.
Key words: Fecal incontinence; Experimental rat model; 
Anal sphincter; Cell implantation; Cell therapy; Stem 
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Core tip: Fecal incontinence is very frequent and asso-
ciated with severe consequences for patients. Surgical 
treatment outcomes are not as good as they should 
be, mainly in the long term. Stem cells could improve 
these results, as demonstrated in other clinical settings. 
We report a simple rat model for experimental anal 
sphincter injury (a surgical section), and characterize 
it from morphological (conventional histology and 
immunofluorescence) and functional (anal manometry) 
points of view. Then, we describe two approaches for 
adipose-derived stem cell administration to the injured 
area (injection and biosutures) and demonstrate stem 
cell survival during at least 7 d, as well as their safety. 
Trébol J, Georgiev-Hristov T, Vega-Clemente L, García-Gómez 
I, Carabias-Orgaz A, García-Arranz M, García-Olmo D. Rat 
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from: URL: http://www.wjgnet.com/1948-0210/full/v10/i1/1.htm 
DOI: http://dx.doi.org/10.4252/wjsc.v10.i1.1
INTRODUCTION
Fecal incontinence is a very prevalent nonfatal illness 
associated with considerable embarrassment, very 
relevant psychosocial repercussions (disability, anxiety, 
depression, social isolation and job loss; it is the second 
cause of institutionalization, etc.) and poor quality of 
life. It is estimated to affect 11%-15% of adults[1] as 
well as 2.2% of the general population and 47% of 
institutionalized people[2], but its real prevalence is 
probably much higher[3]. 
This condition also has a very important economic 
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impact, consisting of direct (diagnostic test, treatments, 
etc.) and indirect (labor production, secondary treat-
ments, etc.) costs. In a Seattle study, annual healthcare 
costs augmented significantly in multivariate analysis, up 
to $2897 of 2005 (pads, barriers or institutionalization 
costs were not included)[4]. In a Dutch study, global costs 
grew €2169 yearly for each patient[5].
Fecal incontinence is a multifactorial disease. The 
most frequent morphological alteration is a sphincter 
lesion, found in almost 60% of patients, most of them 
obstetric (30%-40%). Sphincter lesions during delivery 
ranges from 11%[6] to 26.9%[7] and cause incontinence 
in 76.8%-82.8% of patients[7]. 
Although in the last years sacral neuromodulation 
has been growing exponentially, surgery remains the 
treatment of choice for the most severe or refractory 
cases, mainly if sphincter lesions are present. Sphincter 
repair is the most frequently performed and successful 
technique for traumatic lesions. Sphincter repair has 
good results in the short term, being excellent to 
good in 66%, moderate in 22% and poor in 12% of 
patients[8]. But this outcome does not persist in the long 
term[9] for reasons not well understood.
Stem cell (SC) therapy has demonstrated pro-
mising results in a wide variety of clinical settings. 
Application of adipose-derived stem cells (ASCs), one 
type of mesenchymal stem/stromal cells (MSCs), is a 
novel approach for enhancing regeneration or repair 
of damaged tissues[10-12]. ASCs have been tried in 
environments particularly unfavorable for healing, such 
as experimental colitis[13], sepsis[14], anal fistula[15] and 
Crohn´s[16], with promising results. ASCs have important 
proliferation and differentiation capabilities but also 
immunoregulatory and antiinflammatory properties[17]. 
ASCs are isolated easily from subcutaneous fat, in a 
process that yields 100 times more SCs than bone 
marrow aspirates[18].
Our research group has been working with ASCs 
since 2002 in the clinical and experimental setting and 
has been a pioneer on their use in digestive fistulizing 
diseases[15] and other conditions. We have conducted 
three clinical trials (phases Ⅰ, Ⅱ and Ⅲ)[19-21] with 
autologous ASCs and one with allogeneic (phase Ⅰ-Ⅱ
a)[22], and participated in two with allogeneic[23,24]. All these 
trials included more than 400 treated patients. Sutures 
covered with ASCs (named “biosutures”) were designed 
and tested on colonic[25-26] and tracheal experimental 
anastomosis[27]. All these studies, and many others, have 
proven ASCs to be safe and possibly effective.
Our aim was to test ASCs for fecal incontinence in a 
murine model prior to study of their use in humans. The 
first step was to design an easy and reproducible model 
for sphincter injury, and the second to test two different 
ASCs administration systems. 
MATERIALS AND METHODS
Animals employed
We used 50 adult female BDIX rats (selected for 
cell therapy because they are syngenic to mimic an 
autologous application), weighing 170–260 g and aged 
16-24 wk (provided by Charles River Laboratories 
International, Inc., Wilmington, MA, United States), and 
10 adult female Wistar rats (bred at the animal facility in 
the University Hospital La Paz, Madrid, Spain). Two days 
before surgery, animals were transferred to individual 
cages. They had free access to water and a standard 
diet (Panlab S.L.) and were housed in a restricted 
access room, with controlled temperature (23 ℃) and a 
12-h light/12-h dark cycle.
Ten Wistar and fourteen BDIX rats were employed 
for anatomy studies, surgical damage model creation, 
obtaining ASCs, functional assays, and anesthetic 
dosage adjustments. Thirty-six BDIX rats were used for 
cell therapy and functional studies. 
The present study was performed in accordance 
with the European Union guidelines for reducing pain 
and discomfort to experimental animals (86/609/CEE). 
Animals surpassed all sanitary controls. The study 
protocol was approved by the Ethical Committee for 
Animal Welfare of University Hospital La Paz, Madrid, 
Spain. 
Anesthetic and surgical materials
For anesthesia induction, we used isoflurane (Forane®; 
Abbott Laboratories, Abbott Park, IL, United States) in 
oxygen (3 lpm O2 and 5 lpm Forane® for induction and 
1.5–2 lpm for maintenance). For functional studies, an 
intraperitoneal mixture of ketamine (Ketalar®; Pfizer, 
New York, NY, United States) and xylazine 2% (Xilagesic®; 
Calier, Buenos Aires, Argentina) was selected following 
Wang et al[28] and Zutshi et al[29]. We applied lower 
doses than those used in the mentioned studies: 50 
mg/kg ketamine and 5 mg/kg xylazine for surgery with 
functional registry, and 30 mg/kg plus 3 mg/kg for 
functional study alone.
For surgery, standard microsurgical equipment, a 
10 × to 40 × magnifying lens and 0.5 mL syringes with 
30 G (0.3 mm) and 8 mm needles (BD Micro-FineTM; 
Becton Dickinson, Franklin Lakes, NJ, United States) for 
injecting ASCs were used. For suturing, 6/0 polyglactin 
910 sutures with cylindrical needle (½ circumference 
and 17 mm length) were used (Vycril®; Ethicon, 
Johnson and Johnson, Somerville, NJ, United States).
Functional studies material
We performed basal anal manometry, modifying the 
model pioneered by Vinograd et al[30] and used by Wang 
et al[28] and Zutshi et al[29]. A 0.4 mL latex balloon (Kent 
Scientific Corp., Torrington, CT, United States) was 
connected through a rigid tube to two 3-way stopcocks; 
one of them had a free opening to set 0 values, and 
the other one was connected through one side to an 
infusion pump (that filled the system with normal saline 
solution) and to a Millar SPR-524 pressure transducer 
(Millar Inc., Houston, TX, United States) through the 
other side. The transducer was then connected to an 
amplifier (ML224) and this to a digital pulse detecting 
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system (Powerlab 4/30) with real time recording 
software (Chart v5.5); these three elements were from 
ADInstruments, Sidney, Australia. 
Isolation, culture and marking of ASCs
ASCs were obtained from the subcutaneous fat tissue 
according to a previously described protocol in humans 
by Zuk et al[31], based on their adherence to culture, 
with some minor modifications. Stromal vascular 
fraction (SVF) was obtained and digested with type I 
collagenase (0.075%; Gibco®Thermo Fisher Scientific, 
Waltham, MA, United States). The digested tissue 
was centrifuged and the pellet was resuspended in 
0.16 M NH4Cl for erythrocyte lysis. Then, the cells were 
separated by filtering the product through a 70-μm nylon 
mesh, plated in culture dishes, and cultured at 37 ℃ in a 
humid atmosphere (90%–95%) with 5% carbon dioxide 
in the Gibco™ Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Thermo Fisher Scientific, Waltham, MA, United 
States) containing 10% phosphate buffered saline (PBS), 
2 mmol/L glutamine, and 1% penicillin–streptomycin. 
Nonadherent cells were removed and subcultured 24 h 
after seeding; these were the ASCs.
In order to identify ASCs in animal tissue samples, 
we marked them. In the third subculture at 60% to 
70% confluence, ASCs were infected with enhanced 
green fluorescent protein (eGFP) transducing lentivirus 
(CNIC, Madrid, Spain). Sorting of selected eGFP-ASCs 
(99.6% positive) was applied after another 2 to 3 
passages.
ASCs characterization
Cell cultures were analyzed by four-color flow cytometry 
using a FACS Calibur (Becton Dickinson Biosciences–
BDB, San José, CA, United States) after staining 
with fluorochrome (Alexa Fluor 647; Thermo Fisher 
Scientific) conjugated with two positive markers: anti-
CD90 (BDB) and anti-CD29 (Millipore, Burlington, MA, 
United States) and two negative markers: anti-CD45 
(BDB) and anti-CD11b (BDB). With these four markers 
and the confirmed plastic adherent capability, our cells 
fulfill at least two out of three minimal internationally-
decided defining criteria[32,33]. Differentiation capability 
was proven in prior experiments with the same isolation 
protocol.
Biosuture preparation
Biosutures were obtained by culturing 30 cm 6/0 
polyglactin 910 sutures with 1.5 × 106 eGFP-ASCs on 
ultra-low attachment plates (P6 ULA, Costar®; Corning, 
Corning, NY, United States) over 72 h, according to the 
published protocol with minor changes[25]. Then, the 
sutures were washed with saline and used. Cell viability 
was evaluated by trypan blue. Cell adherence to suture 
and needle was previously confirmed by fluorescence and 
electron microscopy[25,27], and cell density significantly 
decreased after two stitches in muscle tissue[27]. Thus, 
we decided to use each biosuture for only two stitches.
We performed some studies to calculate the real 
cell dose adhered to sutures and studied with immuno-
fluorescence for several biosutures after their use, 
looking for cells, and then counted adhered cells in the 
last centimeter of the remaining suture. 
Cell injection products
eGFP-ASCs (106 cells) diluted in 50 μL normal saline 
were applied in each case. 
Surgical damage model 
After detailed study of the anorectal morphology on 
three Wistar and three BDIX rats, we designed a simple 
procedure, as follows (Figure 1).
Firstly, the animal was placed over a heating blanket, 
in a supine position. Perineal antisepsis was performed. 
The anal canal was emptied and a probe (Abbocath® 
14G or similar) was inserted through it. 
An arciform 10 mm to 15 mm anterior perianal incision 
(3 mm from verge) was performed. A 6/0 stitch at the 
inferior border to the tail was knotted. Adipose tissue 
was dissected sideways (with scissors or gauze) to 
expose approximately 20 mm of anorectal conduit until 
visualization of a thin darker line (external sphincter) or 
up to the anal verge.  
Then, the muscular layer was held with clamps 
and a small incision was made until herniation of the 
submucosa or the probe was visualized by transparency. 
Submucosal dissection was continued longitudinally 
and the muscular layer was sectioned in a longitudinal 
fashion up to the anal verge and near the stitch caudally 
and proximally until completing 10 mm. If a mucosal 
perforation occurred, an interrupted suture was 
performed, leaving knots on the parietal side.
Sphincter repair and cell therapy
Immediate repair was performed with three to four 
interrupted 6/0 stitches. In the biosuture group, one 
suture was used for two stitches and on the second 
one, a back and forth motion was used three to four 
times, trying to deposit more ASCs. For ASC injections, 
two injections were given on each side of the muscle 
incision (Figure 2).
Finally, the skin incision was closed with interrupted 
stitches, burying the knots in the depth (to keep the 
animals from biting the suture). We washed the wound 
with iodine solution and optionally applied an aerosol 
plastic dressing (Nobecutan®; Inibsa, Barcelona, Spain). 
Analgesia (petidine) was injected subcutaneously 
immediately afterwards and on the following day.
Measurement of anorectal pressure; data management
The system was purged to avoid air bubbles, and the 
latex balloon was filled to 20-90 mmHg (to remain 
turgescent). The rectal ampulla was emptied, and the 
balloon was inserted until the silk knot that secures it to 
the tube reached the verge. The registry took between 
30-60 min to reach a stable and regular activity. The 
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system was configured to detect 10 pulses per second, 
registered as mmHg, and at least 30 min of stable 
activity was registered. 
Based on our experience and previously published 
papers, we picked the 12 min most stable registry 
selections as highly representative to study such. The 
area-under-the-contraction waveforms vs time curve 
(AUC), related to the selection baseline and not to 0 
to correct for basal value (related to balloon inflation) 
variability, was obtained from these tracings. Total 
number of contractions (defined as a rise of at least 10 
mmHg) and their frequency were determined for each 
selection. Since AUC could not reveal minor changes in 




Figure 1  Sphincter anal injury model. A: An arciform 10-mm to 15-mm anterior perianal incision (3 mm to 5 mm from the anal verge) was performed; B: Adipose 
tissue was dissected sideways to expose 20 mm of conduit until visualization of the thin, darker line of the external sphincter was achieved (arrow); C: An incision was 
made in the muscular layer until submucosa herniation, then submucosal dissection progressed in a longitudinal fashion, downward (until the anal verge or near the 




Figure 2  Sphincter repair and cell therapies. A–C: If immediate sphincter repair was programmed, it was performed with 3 to 4 stitches of 6/0 interrupted suture; 
A: If biosuture was used, sometimes a bubble formed on the outer aspect of the muscle (arrow); D: If an injection was given, two injections on each side of the muscle 
incision were done; generally, bubble formation was observed; E: Finally, the incision was closed with 6/0 interrupted sutures, burying the knots in the depth. More 
details about surgical and cell therapy techniques are provided in the text.
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in the investigator´s viewpoint. For them, we calculated 
the mean values in each registry of the following: total 
duration (D), time to peak (Tmax), difference between 
maximal and minimal pressure value (range, R), and 
number of peaks (NP) (Figure 3).
Morphological assays
Animals were sacrificed at days 1, 4 or 7. Anorectal 
conduits were extracted, fixed in 4% formaldehyde, and 
embedded in paraffin. 
Histopathology: Slices (5-μm thick) were stained with 
hematoxylin and eosin and examined under a Leica DM 
LS2 microscope. 
Immunofluorescence: Incubation of slices with 
primary antiGFP (SC-8334; Santa Cruz Biotechnology, 
Dallas, TX, United States) and antiα-actin (MAB-1501; 
Millipore) antibodies was carried out overnight and 
then for 1 h with the secondary, antirabbit Alexa Fluor 
488 (Molecular Probes, Eugene, OR, United States) 
and antimouse Alexa Fluor 544 (Molecular Probes). 
Sections were mounted with antifade reagent, with 
4′, 6-diamidino-2-phenylindole (DAPI) (Prolong Gold; 
Molecular Probes) and viewed under a fluorescent 
microscope (Leica DMI6000B). To reduce the effect of 
spontaneous natural fluorescence, we used primary 
antibody omitted sections as negative controls and 
detected GFP presence and not GFP fluorescence 
(sometimes too faint).
Safety studies
Animals were examined for any local or systemic 
abnormality. If death occurred, an autopsy and an exam 
of the operated region were performed. If adverse 
events appeared, they were recorded and exhaustively 
analyzed. If any abnormal tissue was observed, a 
biopsy was done. 
Experimental design
We divided 36 BDIX rats into three groups, with three 
subgroups of 4 animals based on time to sacrifice (1, 4 
or 7 d): (1) group 1, no repair and ASCs injection; (2) 
group 2, repair with biosutures; (3) group 3, repair with 
conventional sutures and ASCs injection.
Statistical analysis
We used Kolmogórov-Smirnov test to assess if normal 
distribution criteria were met. In descriptive analyses, 
means, standard deviation and range were applied. 
To compare groups, we used ANOVA or Kruskal-
Wallis test. P-value significance was 0.05. All statistics 
were performed using SPPS version 15.0 (IBM Corp., 
Armonk, NY, United States).
RESULTS
ASCs characterization
Flow cytometry confirmed eGFP expression > 95% until 
the 15th passage and mesenchymal phenotype by the 
wide expression (> 95%) of CD90 and CD29 and the 
absence (< 5%) of CD45 and CD11b.
Biosuture quality 
Sometimes, we found some clots in the supernatant 
that contained grouped ASCs. Similar structures 
appeared occasionally when using biosutures on the 
outer side of the muscular layer and less frequently with 
injections. 
Cellular distribution over the suture was hetero-
geneous (Figure 4).
Studies of cell count and viability showed the 
following: (1) in culture medium (seven determinations): 
100000 to 280000 (mean 171428.57 with standard 
deviation (SD) 64627.14, viability with blue trypan was 
98%; (2) adhered cells (detached with trypsin, three 
sutures): 820000 to 860000 (mean 840.000 with SD 
20,000), viability was 100%.
We studied seven biosutures under microscopic 
immunofluorescence, prior to and after surgical use, and 
counted the remaining cells in their distal centimeter 
(Figure 4). (1) Some ASCs persistently adhered after 

















Figure 3  Basal anal manometry. A and B: Anal pressure data demonstrate spontaneous rhythmic contractions in the form of “plateaus”, with multiple peaks. At least 
30 min were registered and a segment of 12 min with the highest stability was selected. For these tracings selections, we calculated the area-under-the-contraction 
waveforms vs time curve related to the registry baseline. In A, it is the area between the purple and the red lines. To detect minor changes, we selected the six best 
contractions; for each one of these we determined (B): total duration (D), time to peak (Tmax), pressure range (range, R), and number of peaks. A mean value of 
these variables was calculated in each registry.
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its use, mainly in the proximal two-thirds of the suture. 
(2) cell count of the last centimeter ranged from zero to 
two ASCs per millimeter, so the majority of ASCs on the 
distal end were left on the animal tissue. 
These results confirmed that the maximal dosage 
of ASCs that we could supply was 820000 to 860000, 
which was less than published data with the same 
charge of ASCs (80% of total, 1.2 × 106)[27]. Maybe, it 
could be a bit higher because with 98% to 100% cell 
viability some ASCs could divide.
Sphincter damage model: Morphologic and functional 
results
From a surgery viewpoint, it is frequently difficult to 
identify both sphincters-the external one because it is 
poorly developed (it has a slightly darker color), and the 
internal one because there is no clear continuity solution 
with rectal musculature (Figure 5). To identify anatomy, 
we made multiple coronal and sagittal sections and a 
10 × reconstruction of hematoxylin and eosin imprints. 
It was very similar to that of humans, with the anal 
canal being 3 to 5 mm long and surrounded by two 
sphincters. The internal one consisted of smooth muscle, 
was an enlargement of the circular enteric musculature, 
and ended about 1 mm proximal to the anal verge. 
Immediately external to it, there are some longitudinal 
smooth fibers, and external to them the striated muscle 
bundles of the external sphincter, which ends close to 
the anal verge and has two to three different parts. A 
transition zone marks the change from rectum to anus, 
and there are some anal glands closer to it.
With the designed procedure (1 cm section), both 
A CB
Figure 4  Biosuture samples. With the described protocol, cellular distribution over the suture was heterogeneous (A and B) and sutures were not fully covered; 
instead, there were “lumps” with clustered ASCs in the supernatant. After surgical use (C), some ASCs remained adhered and partially covering the suture, mainly in 









Figure 5  Anatomy and injury model study. Sometimes it is difficult to identify the external anal sphincter (see Figure 2), but it is present and included in the section 
as can be seen in A: A sagittal section; or in B: Coronal hematoxylin and eosin reconstruction (10 ×). The described model implies section of internal anal sphincter 
(C: Hematoxylin and eosin 10 ×) and external anal sphincter (D: Hematoxylin and eosin 10 ×). This was also evidenced on immunofluorescence staining at 10 × (E 
belongs to a non-repaired rat and F to a biosuture group rat; suture strains can be seen with green autofluorescence). EAS: External anal sphincter; IAS: Internal anal 
sphincter; AS: Anal sphincter.
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Table 1  Functional studies (anal manometry)
Number of contractions Frequency, n  /min   Duration in s Time to max in s Peaks number, n   Range of mmHg      AUC
Preoperative
Number 6 6         6           6           6           6       6
Mean        9.489            .6980         26.6452             8.88255           2.52           25.9462   4884.90
Standard deviation            .59              0.5698           6.669000             2.9265056             .5254           6.6895   8.86004
Minimum      9.0        0.9         .0000             4.266             .             6.2   22.46
Maximum    50.0        4.         4.2800           5.6           2.6          .9 590.69
Postoperative
Number 6 6           4             4             4             4       2
Mean          0.55            0.0446         26.425000             9.056250             .5000           2.950     48.29
Standard deviation            .506              0.25           5.80550             4.25222             2.4828             2.0952     6.06246
Minimum   0        0.00         20.4000             6.050             5.00            0.9       2.9
Maximum      6.0        0.50         .6000           5.500           0.50            5.2   60.80
A descriptive analysis is presented. In the first two columns, total number of contractions (defined as a rise higher than 10 mmHg) and their frequency 
are presented (studied within the 2-min selection). The following four columns focus on contraction characteristics: contraction duration, time to reach 
maximum from the beginning, number of twitches in each contraction, and range (maximum minus minimum). These values were calculated by selecting 
the six best contractions on each registry. Finally, the area under the pressure vs time curve (-AUC- calculated with the 2-min selection) values are 
presented. All of these variables are presented in basal (preoperative) and postoperative conditions.
sphincters were always sectioned, as confirmed by 
morphological studies (Figure 5).
Regarding functional assays, spontaneous, rhythmic 
contractions in the form of “plateaus” with multiple 
fasciculation-producing peaks appeared (Figure 6). 
These basal contractions were very heterogeneous, 
as we can see in Table 1, with a frequency of 0.91 
to 4.17 per min (mean 1.6980 with SD 0.57698), a 
mean duration of 26.67 seconds, and a mean number 
of peaks of 12.53. Mean registered amplitude was 
25.95 mmHg and the Tmax was 8.88 seconds with 
SD 2.93. Probably the most important component of 
this activity was the internal sphincter, but both could 
contribute. Postoperatively, findings were consistent 
with total sphincter lesion, irrespective of the applied 
treatment; the described activity disappeared and 
was substituted by a gentle oscillation of the basal line 
without a recognizable pattern (Figure 6). Only in 4 out 
of 36 animals did some small contractions appear (Table 
1). There were no differences between groups at the 
immediate postoperative measurements (P = 0.329–
0.73 on ANOVA). AUC decreased to less than one-
tenth in the lesion group, without significant differences 
between groups (P = 0.134).  
Cell tracking on animal samples 
We analyzed the presence of GFP+ cells in 19 rats (Figure 
7), finding them in 16 (84.21%) and in 100% of the 7 
sacrificed at 7 d.
Regarding GFP+ cells’ location, the majority of 
animals had many simultaneously. The most frequent 
were muscular section endings and the tissue between 
them (10/16 animals), then submucosa (9/16 animals), 
and surrounding sutures (6/16 animals; 100% of the 
5 animals with biosutures). We could not find them 
at the mucosa. Concerning spatial disposition, the 
most frequent was in small groups (10/16) or making 
“conglomerates” (8/16; 5/6 of group 1 and 3/5 of group 
3). Three animals presented with perivascular disposition.
We could not identify cells simultaneously expressing 







Figure 6  Functional studies (anal manometry). A and B: Once the time for registry stabilization (30 to 60 min) was surpassed, spontaneous, rhythmic contractions 
in the form of “plateaus” with multiple fasciculations (peaks) appeared; C and D: Postoperatively, findings were consistent with a total sphincter lesion, the activity 
disappeared and was substituted by a gentle oscillation of basal line, without a recognizable pattern and irrespective of the applied treatment. To visualize the values 
of registries analyzed parameters see Table 1.
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GFP and α-actin.    
Safety 
Five deaths took place (13.88%), without relevant 
findings on postmortem studies and unrelated to the 
treatment received; eighty percent were probably 
related to anesthetic drugs.
We found 17 adverse events, affecting 13 rats 
(incidence 36.11%). None of them were considered 
severe. In order of frequency, they were: fecal impaction; 
hypotonic anus and anal laceration (3 cases of each); 
perianal laceration, perianal phlegmon, and cutaneous 
suture dehiscence (2 cases of each) and 1 case of anal 
stenosis. We considered 2 cases attributable to received 
treatment (muscular suture), 3 cases doubtfully related, 
and 12 cases non-related. None seemed attributable to 
ASCs. 
No significant differences were found between 
groups in the incidence of mortality or adverse events. 
So, SC therapy on this model was completely safe.
DISCUSSION
The anatomy of rat anal sphincters is similar to that of 
humans. The most remarkable differences are that the 
external sphincter is poorly developed and the internal 
sphincter is difficult to distinguish from the rectal 
muscular layer. Using the 1-cm section from the anal 
verge, we can include both, even though they are not 
well identified.
Related to function, several publications reflect that 
the external sphincter’s contribution to basal tone in 
rats seems higher than in humans[29,30]. We decided 
to use the anesthetic ketamine/xylazine mixture, 
250 μm 25 μm
100 μm 50 μm
250 μm100 μm
Figure 7  Immunolocalization of ASCs at surgical site. Cell nuclei were stained with DAPI (blue), ASCs with eGFP (green), and muscle with α-actin (red). On 
injected animals, ASCs tended to form “conglomerates” in the submucosa and were able to survive at least 7 d (A: G1 group rat sacrificed at 7 d). ASCs appeared in 
injury foci, even though they were deposited at some distance (e.g., in “conglomerates”): In muscle section margins (B: G2 sacrificed at 7 d and C: G1 sacrificed at 
1 d). In the biosuture group, ACSs also surround the suture (D: G2 sacrificed at 4 d). ASCs also appeared in the tissue that filled the space between muscle section 






Trébol J et al . Rat model of anal sphincter injury and cell therapy
0 January 26, 208|Volume 0|Issue |WJSC|www.wjgnet.com
because it was the one we found to provide more stable 
registries. This mixture was also used by Zutshi and 
colleagues[29,34-36], but other authors have employed 
ketamine with better results than ours[37]. 
Our results were similar to other publications with 
regard to detected activity. However, numeric values 
were in some cases very dissimilar, probably due to 
the different rat species employed (BDIX vs Sprague-
Dawley) or slight methodological variations. Our 
frequency was similar to that of Vinograd (0.91–4.17 
per min compared with 1–3[30]) or Zutshi et al[29], also 
duration (26.67 with SD 6.67 compared to 35.10 ± 
2.53[29] or 26.23 ± 1.68[36]) and Tmax (8.88 second, SD 
2.93, compared to 10[29] or 12.24 ± 0.078[36]). But our 
mean NP was higher (12.53 SD 3.53 compared to 8.9 ± 
0.5[29] or to 7.22 ± 0.45[36]) and our range was also much 
wider (25.95, SD 16.69 compared to 10.01 ± 0.66[29] or 
to 12.0 ± 0.1[37]).
In our experiments, practically all spontaneous 
activity disappeared after surgery (irrespective of the 
reparation or SC presence). Nevertheless, Zutshi et 
al[29] and others[34] found some pressure waves, despite 
muscle disruption. The only possible explanation for 
this phenomenon is the difference in the injury, as they 
practice “a precise 3-mm to 4-mm incision” for selective 
sphincter section that might not be complete. 
Compared with other published works using SCs 
for fecal incontinence in rats, our lesion is one of the 
most extensive. Lorenzi et al[38] described a left lateral 
selective sphincterotomy without specifying the length 
used later by Mazzanti et al[39]. Kang et al[40] performed 
cryoinjury without specifying the damaged volume; 
later, Bisson et al[41] published that cryoinjury must 
be at least 90º to be significant. Zutshi´s model[29] 
was also employed in other publications[34]. White et 
al[42] and Pathi et al[43] performed a total section of 7 
mm, followed by rectal mucosa repair. Going further, 
Lane et al[37] performed a more aggressive injury 
(“proctoepisiotomy”) without describing technical details 
and extension; Salcedo et al[36] applied an even more 
aggressive procedure involving an excision of 25% of 
both sphincters, but they did not perform an immediate 
postoperative control so we could not compare our 
functional results with theirs. 
Aiming to minimize the effects of the poorly 
developed sphincters, some authors have tested bigger 
animals (rabbits[44-46] and dogs[47,48]), but there are only 
five published papers compared to ten for rats. 
We can discuss clinical relevance of our injury 
model. Human obstetric trauma is more complex than a 
simple section during episiotomy or a perineum tear, it 
combines muscle injury, regional hypoxia, denervation, 
etc. Other factors could be added later in life, such as 
ageing, hormonal changes, surgeries, etc. 
On the other hand, in the clinical setting, immediate 
repair offers better results, but the most frequent 
scenario is a repair indicated years later. This could 
modify some confounding factors that we have 
observed with immediate repair (mucosal tears, fecal 
contamination, etc.) that could compromise ASCs 
survivorship or effects. 
In an effort to reproduce these complex effects, 
simulated childbirth injury models have been designed, 
mainly for urinary incontinence. It was first described by 
Resplande et al[49], who inserted an inflated 10F Foley 
catheter inside the vagina over 3 to 4 h to simulate 
labor; an episiotomy and extraction of inflated Foley 
was performed. Later, Healy et al[50] published a model 
for fecal incontinence using two intrapelvic, retrouterine 
balloons (6 Fr urinary catheters) placed through a 
3-cm laparotomy over 1 h. We tested the model of 
Resplande, but we decided not to use it anymore 
because we observed high variability in injuries. We 
think that our model results in a more homogeneous 
injury. More studies on simulated childbirth models may 
be needed and also consideration of a delayed repair, as 
some authors have performed[51].
Regarding SC vehicles, we have employed biosutures 
and injections, finding GFP+ cells during at least 7 d 
with both. Biosutures can be used in a similar fashion to 
conventional sutures. The pioneer model with biosutures 
and colonic anastomoses studied in the short-term 
found fewer adherences on days 4 and 7 (preserving 
anastomotic resistance[25]), which was significantly 
greater on day 4 in a poor adhesion environment[26]. 
Later, tracheal anastomoses were studied for 60 d 
and a swift inflammatory response was found: on 
postoperative days 1 and 4, acute inflammation was 
substituted by chronic inflammation[27]. Yao et al[52] 
used embryonic SCs, added molecules to improve cell 
adherence (poly-L-lysine and fibronectin)[53], and applied 
them to rat tendons. Horváthy et al[54] employed bone 
marrow-MSCs and observed better cell adherence if the 
suture was covered with albumin and the SC surviving 
in implanted tissues during 5 wk. They recommended 
a 48 h culture as the best for clinical usage (over 168 
h, 910 polyglactin loses resistance)[55]. No evidence 
exists about the best dose. However, we found that 
some cells tend to form “clusters” over the suture, in 
the culture medium and also remaining ASCs adhered 
to the sutures after their usage. These findings make 
us wonder about the suitability of this vehicle, so more 
studies on suture preparation are needed. Delivered cell 
dose could be more controlled by injection, but similar 
clusters can be observed sometimes, losing ASCs.    
Now the questions that arise are how to get better 
SC delivery, survival, and function in tissues. An 
interesting approach is molecule addition to sutures, 
such as vascular endothelial growth factor (VEGF) 
by Bigalke et al[56]. Cytokines could also be of high 
relevance, mostly in models with delayed repair because 
they could already be normalized; some examples 
are stromal-derived factor-1 (SDF-1) and monocyte 
chemotactic protein-3 (MCP-3)[57]. As an example, Sun 
et al[58] performed a 50% excision of the anal sphincter, 
and they compared SDF-1 alone or combined with 
MSCs 3 wk later with interesting results. 
Published animal investigations in this field have 
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employed muscle progenitors in 10 papers and BM-
MSCs in 5 papers. All except one confirm the safety. 
Concerning results, generally good morphological and 
functional responses have been observed with questions 
about cell survival and only one long-term study[46]. In 
human research, there is one study unrelated to fecal 
incontinence that finds improvement with ASCs[20], 
three incontinence studies involving 38 patients with 
promising results[59-62], and seven ongoing clinical trials. 
There are many questions remaining about the 
mechanism of action of ASCs, which is not totally 
understood nowadays. Their multi-lineage differentiation 
potential coupled with their immune-privilege and 
their ability to stimulate resident progenitor cells 
through paracrine secretion, as well as their angiogenic 
potential, are important. There is growing evidence 
about their immunomodulation capability. It is thought 
to be largely based on inhibition of T cell and B cell 
proliferation and dendritic cell maturation[63] and in the 
secretion of cytokines[64]. For example, Nemeth et al[65] 
observed MSCs’ sepsis attenuation by macrophages 
reprogramming to increase IL-10, a cytokine that 
decreases neutrophil migration to tissues. There is 
much interest in identifying secretome and immu-
nosuppressive properties of ASCs. Our research team 
has added some contributions. Georgiev-Hristov et 
al[27] showed an early switch from acute to chronic 
inflammation in the presence of ASCs after tracheal 
anastomosis. And, Riera del Moral et al[66] observed less 
acute and chronic inflammation and increasing fibrosis 
of aneurysm sacs in pigs. 
Finally, our present results show that SC therapy on 
this model is safe, as no serious adverse reactions or 
neoplastic processes were observed. In this field, there 
is a worrisome paper in which 2/24 rats receiving 5 
× 106 myogenic SCs developed local abnormal foci of 
growth that were benign[67]. 
Our proposed surgical procedure produces a 
consistent lesion of both sphincters and could be a 
model for posttraumatic fecal incontinence. Biosutures 
and injections are both suitable for cell delivery. 
Biosutures do not change the surgical technique or 
suture manageability. ASCs are able to survive in the 
complex area of anal sphincters, at least 7 d, and are 
safe in this clinical setting.
ARTICLE HIGHLIGHTS
Research background
Fecal incontinence is a very prevalent (11% to 15% of adults), nonfatal illness 
associated with devastating consequences mainly in the psychosocial sphere 
and quality of life. Although in the last years sacral neuromodulation has been 
improving the poor results of available treatments, surgery remains the choice 
for the most severe or refractory cases, mainly if sphincter lesions are present 
(the most frequently observed anatomic alteration). Sphincter repair is the most 
successful technique used for traumatic fecal incontinence, but its results are 
not very satisfactory, mainly in the long term. Stem cells (SCs) and adipose-
derived stem cells (ASCs) have demonstrated promising results in a wide 
variety of clinical settings, including particularly unfavorable environments for 
wound healing, such as anal fistulas and Crohn´s disease.
Research motivation
To test if SC therapy could improve postoperative healing mechanisms in 
patients with fecal incontinence. If this hypothesis is correct, surgical outcomes 
could be improved and more patients would benefit from surgery in the short 
and long term. 
Research objectives 
The first objective was obtaining an in-depth knowledge of rat anal region 
anatomy so as to design an easy and reproducible model for fecal incontinence 
or sphincter injury. The second objective was to establish a method for 
studying rat anal sphincter function, defining the best anesthetic method and 
physiological test to be used with low morbidity. Finally, the main objective 
was to study the feasibility and safety of ASC administration to rat anal 
sphincters via different methods. All of the previously mentioned objectives 
were accomplished. This furnishes future investigations with the proposed 
animal model for study of potential SC efficacy; and, if the expected results are 
obtained, they will support trying this therapy on humans.
Research methods
Rat anal region normal anatomy was studied on BDIX and Wistar female 
rats. Once anatomy was well known, the authors studied a system capable 
of detecting the low-pressure waves supposed to be created in this area, 
and the capability of this system to detect sphincter lesions. Simultaneously, 
the authors needed to select a model for fecal incontinence. Since simulated 
childbirth injury models are complex, associate morbidity in animals and 
generate highly variable injuries, the authors decided to create a simple 
model of sphincter injury. The authors tested different injury models and finally 
selected an anterior extra-mucosal longitudinal myotomy of 1 cm. Researchers 
studied its morphology and physiology to verify if this procedure injured both 
sphincters in a constant way. Going further, to decide the best system to detect 
sphincter pressures, the authors tested different anesthetic drugs (inhaled 
isoflurane, intraperitoneal ketamine, intraperitoneal ketamine plus xylazine) 
and different systems to detect pressure, including an endorectal balloon that 
was retired slowly (similar to human manometry), a normal saline infusion 
through a mini-laparotomy in the rectum (until anus became opened by rectal 
increasing pressure), and basal anal manometry with a stationary endoanal 
balloon. Preliminary studies led the authors to select intraperitoneal ketamine 
plus xylazine (provided the most stable functional registries) and basal anal 
manometry with a stationary endoanal balloon as the best options. ASCs 
were obtained from subcutaneous fat from two BDIX rat males and later were 
marked with eGFP. Later, preparations of 106 ASCs in 50 µL of normal saline 
or biosutures of polyglactin 910 6/0 suture covered with 1.5 × 106 ASCs were 
prepared. Finally, those preparations were applied to 36 BDIX virgin female 
adult rats that underwent functional studies prior to and after the surgery. Then, 
safety and cell tracking studies were performed during a follow-up period 
lasting 7 d. Animals were distributed among three groups: biosuture repair; 
cell injection without repair; and conventional suture repair and cell injection. 
Moreover, some quality studies were performed with biosutures, trying to 
establish the real cell dose administered during their use.
Research results
A dose of 820000 to 860000 ASCs adhered to the suture, but not all of them 
remained on the animal tissue. The described lesion produced a constant injury 
to both anal sphincters. Rat anal sphincter spontaneous function is composed 
of heterogeneous, spontaneous, consistent, and rhythmic contractions in the 
form of “plateaus”, with multiple fasciculations that disappeared consistently 
with the described surgical damage. ASCs are able to survive in this potentially 
septic area for at least 7 d. We were able to identify them in 84% of the studied 
animals, mainly in the muscular section area or in the tissue that appeared 
between both muscular endings. ASCs form a kind of “conglomerate” in rats 
treated with injections, while they wrapped around the suture in the biosuture 
group. ASCs were also able to migrate to the damaged zone, and the most 
frequent disposition was formation of small groupings. No relevant adverse 
events or mortality could be related to the SCs in our study. We also did not find 
unexpected tissue growths. So, this cell therapy was deemed as safe, at least 
in the short term. As unresolved issues, safety must be studied in the long term, 
ASC survival must be confirmed in longer follow-ups, systems to improve SC 
function and survival could be tested, and biosuture cell dosing must be studied 
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thoroughly.
Research conclusions
The authors propose an easy, reproducible and safe method for rat sphincter 
injury that could represent a model for posttraumatic fecal incontinence. ASC 
administration through cell injections or biosutures is feasible and safe. Both 
systems are suitable for cell delivery, and biosutures do not change the surgical 
technique or suture manageability. Applied ASCs are able to survive in this 
complex area. By this approach, ASCs could offer a benefit for postoperative 
healing in fecal incontinence. 
Research perspectives
The model for rat anal sphincter injury can be used in future experiments for 
testing potential SC efficacy and obtaining long-term results. Anesthetic and 
functional study methodologies may need some minor changes. Areas prone 
to be studied deeply are: obtaining knowledge about the potential mechanism 
of action of ASCs; improving SC delivery, survival and function in the receiving 
animals (cytokine or molecule addition, etc.); and, supplying SCs through 
minimally invasive methods. This study allows continuing studies on animal 
models prior to human use, and, if the expected results are obtained, support 
trying this therapy on humans (only in empirical and highly controlled settings).
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